DAPK catalytic activity in the hippocampus increases during the recovery phase in an animal model of brain hypoxic-ischemic injury

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1600, Issue 1-2, 2002, Pages 128-137

  Schumacher, Andrew M ^a   Velentza, Anastasia V ^a   Watterson, D Martin ^a   Wainwright, Mark S ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Calcium; Calmodulin; Death associated protein kinase; Differentiation; Kinase inhibitor; Neuron; Perinatal cerebral hypoxia ischemia; Stroke

Indexed keywords

11 (3 IMINO 5,6 DIHYDRO 3H BENZO[H]CINNOLIN 2 YL) 1 (4 PYRIMIDIN 2 YLPIPERAZIN 1 YL)UNDECAN 1 ONE; DEATH ASSOCIATED PROTEIN KINASE; ENZYME INHIBITOR; NERVE GROWTH FACTOR; PIPERAZINE DERIVATIVE; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; PROTEIN KINASE (CALCIUM,CALMODULIN);

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BRAIN HYPOXIA; BRAIN ISCHEMIA; CATALYSIS; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; NERVE CELL DIFFERENTIATION; NERVE REGENERATION; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RAT; UPREGULATION; ANIMAL; ARTICLE; BINDING SITE; BRAIN; CELL DIFFERENTIATION; CELL STRAIN; CHEMICAL STRUCTURE; CHEMISTRY; COMPARATIVE STUDY; DRUG ANTAGONISM; ENZYME ACTIVATION; ENZYMOLOGY; KINETICS; METABOLISM; PATHOLOGY; WISTAR RAT;

ANIMALIA;

ANIMALS; ANIMALS, NEWBORN; APOPTOSIS REGULATORY PROTEINS; BINDING SITES; BRAIN; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; CATALYSIS; CELL DIFFERENTIATION; ENZYME ACTIVATION; ENZYME INHIBITORS; HIPPOCAMPUS; HYPOXIA-ISCHEMIA, BRAIN; KINETICS; MODELS, MOLECULAR; NERVE GROWTH FACTOR; PC12 CELLS; RATS; RATS, WISTAR; UP-REGULATION;

EID: 0037020695     PISSN: 15709639     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1570-9639(02)00453-3     Document Type: Conference Paper

References (55)

1. Lee J.-M., Grabb M.C., Zipfel G.J., Choi D.W. Brain tissue responses to ischemia. J. Clin. Invest. 106:2000;723-731.
2. Gorelick P.B. Stroke prevention therapy beyond antithrombotics: unifying mechanisms in ischemic stroke pathogenesis and implications for therapy. Stroke. 33:2002;862-875.
3. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke. 30:1999;2752-2758.
4. Rice J.E. III, Vannucci R.C., Brierley J.B. The influence of immaturity on hypoxic-ischemic brain damage in the rat. Ann. Neurol. 9:1981;131-141.
5. Chan P.H. Reactive oxygen radicals in signaling and damage in the ischemic brain. J. Cereb. Blood Flow Metab. 21:2001;2-14.
6. Choi D.W. Ionic dependence of glutamate neurotoxicity. J. Neurosci. 7:1987;369-379.
7. Choi D. Calcium: still center-stage in hypoxic-ischemic neuronal death. Trends Neurosci. 18:1995;58-60.
8. Kristián T., Siesjö B.K. Calcium in ischemic cell death. Stroke. 29:1998;705-718.
9. Nicholson C., Bruggencate G.T., Steinberg R., Stockle H. Calcium modulation in brain extracellular microenviroment demonstrated with ion-selective micropipette. Proc. Natl. Acad. Sci. U. S. A. 74:1977;1287-1290.
10. Yamamoto M., Takahashi H., Nakamura T., Hioki T., Nagayama S., Ooashi N., Sun X., Ishii T., Kudo Y., Nakajima-Iijima S., Kimchi A., Uchino S. Developmental changes in distribution of death-associated protein kinase mRNAs. J. Neurosci. Res. 58:1999;674-683.
11. Ferrer I., Serrano T., Soriano E. Naturally occurring cell death in the subicular complex and hippocampus in the rat during development. Neurosci. Res. 8:1990;60-66.
12. Gould E., Woolley C.S., McEwen B.S. Naturally occurring cell death in the developing dentate gyrus of the rat. J. Comp. Neurol. 304:1991;408-418.
13. Raff M.C., Barres B.A., Burne J.F., Coles H.S., Ishizake Y., Jacobson M.D. Programmed cell death and the control of cell survival: lessons from the nervous system. Science. 262:1993;695-700.
14. 2-ceramide-induced apoptosis in PC12 cells. Eur. J. Biochem. 269:2002;139-147.
15. Pelled D., Raveh T., Riebeling C., Fridkin M., Berissi H., Futerman A.H., Kimchi A. Death-associated protein (DAP) kinase plays a central role in ceramide-induced apoptosis in cultured hippocampal neurons. J. Biol. Chem. 277:2002;1957-1961.
16. ARF/p53-mediated apoptotic checkpoint to suppress oncogenic transformation. Nat. Cell Biol. 3:2001;1-7.
17. Cohen O., Inbal B., Kissel J.L., Raveh T., Berissi H., Spivak-Kroizaman T., Feinstein E., Kimchi A. DAP-kinase participates in TNF-α- and Fas-induced apoptosis and its function requires the death domain. J. Cell Biol. 146:1999;141-148.
18. Johnston M., Trescher W., Ishida A., Nakajima W. Neurobiology of hypoxic-ischemic injury in the developing brain. Pediatr. Res. 49:2001;735-741.
19. Romijn H.J., Hofman M.A., Gramsbergen A. At what age is the developing cerebral cortex of the rat comparable to that of the full-term human baby? Early Hum. Dev. 26:1991;61-67.
20. Barone F.C., Feurerstein G.Z. Inflammatory mediators and stroke: new opportunities for novel therapeutics. J. Cereb. Blood Flow Metab. 19:1999;819-834.
21. Levine S. Anoxic-ischemic encephalopathy in rats. Am. J. Pathol. 36:1960;1-17.
22. Gidday J.M., Shah A.R., Maceren R.G., Wang Q., Pelligrino D.A., Holtzman D.M., Park T.S. Nitric oxide mediates cerebral ischemic tolerance in a neonatal rat model of hypoxic preconditioning. J. Cereb. Blood Flow Metab. 19:1999;331-340.
23. Vannucci R.C., Towfighi J., Vannucci S.J. Hypoxic preconditioning and hypoxic-ischemic brain damage in the immature rat: pathologic and metabolic correlates. J. Neurochem. 71:1998;1215-1220.
24. Gidday J.M., Fitzgibbons J.C., Shah A.R., Park T.S. Neuroprotection from ischemic brain injury by hypoxic preconditioning in the neonatal rat. Neurosci. Lett. 168:1994;221-224.
25. Gidday J.M., Fitzgibbons J.C., Shah A.R., Kraujalis M.J., Park T.S. Reduction in cerebral ischemic injury in the newborn rat by potentiation of endogenous adenosine. Pediatr. Res. 38:1995;306-311.
26. Schmued L.C., Hopkins K.J. Fluoro-Jade B: a high affinity fluorescent marker for the localization of neuronal degeneration. Brain Res. 874:2000;123-130.
27. Gavrieli Y., Sherman Y., Ben-Sasson S.A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol. 119:1992;493-501.
28. Greene L.A., Tischler A.S. Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Proc. Natl. Acad. Sci. U. S. A. 73:1976;2424-2428.
29. Watterson D.M., Collinge M., Lukas T.J., Van Eldik L.J., Birukov K.G., Stepanova O.V., Shirinsky V.P. Multiple gene products are produced from a novel protein kinase transcription region. FEBS Lett. 373:1995;217-220.
30. Van Eldik L.J., Fok K.F., Erickson B.W., Watterson D.M. Engineering of site-directed antisera against vertebrate calmodulin by using synthetic peptide immunogens containing an immunoreactive site. Proc. Natl. Acad. Sci. U. S. A. 80:1983;6775-6779.
31. Velentza A.V., Schumacher A.M., Weiss C., Egli M., Watterson D.M. A protein kinase associated with apoptosis and tumor suppression: structure, activity, and discovery of peptide substrates. J. Biol. Chem. 276:2001;38956-38965.
32. Mirzoeva S., Sawkar A., Zasadzki M., Guo L., Velentza A.V., Dunlap V., Bourguignon J.-J., Ramstrom H., Haiech J., Van Eldik L.J., Watterson D.M. Discovery of a 3-amino-6-phenyl-pyridazine derivative as a new synthetic derivative antineuroinflammatory compound. J. Med. Chem. 45:2002;563-566.
33. Tereshko V., Teplova M., Brunzelle J., Watterson D.M., Egli M. Crystal structures of the catalytic domain of human protein kinase associated with apoptosis and tumor suppression. Nat. Struct. Biol. 8:2001;899-907.
34. Bergeron M., Ferriero D.M., Vreman H.J., Stevenson D.K., Sharp F.R. Hypoxia-ischemia, but not hypoxia alone, induces the expression of heme oxygenase-1 (HSP32) in newborn rat brain. J. Cereb. Blood Flow Metab. 17:1997;647-658.
35. Towfighi J., Housman C., Vannucci R.C., Heitjan D.F. Effect of unilateral perinatal hypoxic-ischemic brain damage on the gross development of opposite cerebral hemisphere. Biol. Neonate. 65:1994;108-118.
36. 1 receptor binding reduces hypoxic-ischemic brain injury in newborn rats. Brain Res. 759:1997;309-312.
37. Volpe J.J. Hypoxic-ischemic encephalopathy. Neurology of the Newborn. 1995;211-369 WB Saunders, Philadelphia, PA.
38. Cheng Y., Desmukh M., D'Costa A., Demaro J.A., Gidday J.M., Shah A., Sun Y., Jacquin M.F., Johnson E.M., Holtzman D.M. Caspase inhibitor affords neuroprotection with delayed administration in a rat model of neonatal hypoxic-ischemic brain injury. J. Clin. Invest. 101:1998;1992-1999.
39. Cheng Y., Gidday J.M., Yan Q., Shah A.R., Holtzman D.M. Marked age-dependent neuroprotection by brain-derived neurotrophic factor against neonatal hypoxic-ischemic brain injury. Ann. Neurol. 41:1997;521-529.
40. 2+/ calmodulin-dependent, cytoskeletal-associated protein kinase, with cell death-inducing functions that depend on its catalytic activity. EMBO J. 16:1997;998-1008.
41. Jin Y., Blue E.K., Dixon S., Hou L., Wysolmerski R.B., Gallagher P.J. Identification of a new form of death associated protein kinase that promotes cell survival. J. Biol. Chem. 276:2001;39667-39678.
42. Maroney A.C., Finn J.P., Connors T.J., Durkin J.T., Angeles T., Gessner G., Xu Z., Meyer S.L., Savage M.J., Greene L.A., Scott R.W., Vaught J.L. CEP-1347 (KT7515), a semisynthetic inhibitor of the mixed lineage kinase family. J. Biol. Chem. 276:2001;25302-25308.
43. Harris C.A., Deshmukh M., Tsui-Pierchala B., Maroney A.C., Johnson E.M. Jr. Inhibition of the c-jun N-terminal kinase signaling pathway by the mixed lineage kinase inhibitor CEP-1347 (KT7515) preserves metabolism and growth of trophic factor-deprived neurons. J. Neurosci. 22:2002;103-113.
44. Ferrell J.E. Jr. Tripping the switch fantastic: how a protein kinase cascade can convert graded inputs into switch-like outputs. Trends Biochem. Sci. 21:1996;460-466.
45. Xu D.G., Crocker S.J., Doucet J.-P., St-Jean M., Tamai K., Hakim A.M., Ikeda J.E., Liston P., Thompson C.S., Korneluk R.G., MacKenzie A., Robertson G.S. Elevation of neuronal expression of NAIP reduces ischemic damage in the rat hippocampus. Nat. Med. 3:1997;997-1004.
46. Watterson D.M., Mirzoeva S., Guo L., Whyte A., Bourguignon J.-J., Hibert M., Haiech J., Van Eldik L.J. Ligand modulation of glial activation: cell permeable, small molecule inhibitors of serine-threonine protein kinases can block induction of interleukin 1β and nitric oxide synthase II. Neurochem. Int. 39:2001;459-468.
47. Teng K.K., Greene L.A. KT5926 inhibits nerve growth factor-dependent neurite elongation. J. Neurosci. 14:1994;2624-2635.
48. Koizumi S., Contreras M.L., Matsuda Y., Hama T., Lazarovici P., Guroff G. K-252a: a specific inhibitor of the action of nerve growth factor on PC12 cells. J. Neurosci. 8:1988;715-721.
49. Wermuth C.-G. Search for new lead compounds: the example of the chemical and pharmacological dissection of aminopyridazines. J. Heterocycl. Chem. 35:1998;1091-1100.
50. Honig L.S., Rosenberg R.N. Apoptosis in neurologic disease. Am. J. Med. 108:2000;317-330.
51. Friguls B., Justicia C., Pallas M., Planas A.M. Focal cerebral ischemia causes two temporal waves of Akt activation. NeuroReport. 12:2001;3381-3384.
52. Koroshetz W.J., Moskowitz M.A. Emerging treatments for stroke in humans. Trends Pharmacol. Sci. 17:1996;227-233.
53. Cohen P. Protein kinases - the major drug targets of the twenty-first century? Nature Rev. 1:2002;309-315.
54. Scapin G. Structural biology in drug design: selective protein kinase inhibitors. Drug Discov. Today. 7:2002;601-611.
55. Nicholls S.A., Sharp K.A., Honig B. Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons. Proteins. 11:1991;281-296.